Health‐related quality of life with fixed‐duration venetoclax‐obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Health‐related quality of life with fixed‐duration venetoclax‐obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial

Published:2021-06-22 Issue:9 Volume:96 Page:1112-1119
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Al‐Sawaf Othman¹^ORCID,Gentile Brittany²,Devine Jacob²,Zhang Can¹,Sail Kavita³,Tandon Maneesh⁴,Fink Anna‐Maria¹,Kutsch Nadine¹,Wendtner Clemens‐Martin⁵,Eichhorst Barbara¹,Hallek Michael¹,Fischer Kirsten¹

Affiliation:

1. Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf; German CLL Study Group University of Cologne Cologne Germany

2. Genentech Inc South San Francisco California USA

3. AbbVie Inc. North Chicago Illinois USA

4. Roche Products Limited Welwyn Garden City UK

5. Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine Klinikum Schwabing Munich Germany

Funder

AbbVie

F. Hoffmann-La Roche

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26260

Reference22 articles.

1. Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

2. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study

3. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

4. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

5. Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yr

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Artificial intelligence assisted diagnosis of chronic lymphocytic leukemia in a historic pediatric case using large language models;Annals of Hematology;2024-07-29

2. Defining treatment success in chronic lymphocytic leukemia: exploring surrogate markers, comorbidities, and patient-centered endpoints;Expert Review of Hematology;2024-06-13

3. Analyses of quality of life in cancer drug trials - a review of measurements and analytical choices in post-reimbursement studies;BMC Cancer;2024-03-06

4. Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL;Blood;2023-09-28

5. First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era;Cancers;2023-07-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3